What We Do

The International Vaccine Access Center accelerates equitable and sustainable access to vaccines in low- and middle-income countries by generating, synthesizing, and using evidence to inform decision making and action.

Our Approach Blends
  • Rigorous science
  • Productive partnership
  • Clear communication
  • Capacity building and training

Our Practice Areas

Country Support

Based on demand from country leaders and health agencies around the world, we provide independent policy advice, support country vaccine decision-making and governance, and connect partners to accelerate progress toward health and development goals.

Coverage & Equity

To improve equitable immunization within and between countries, we help countries better measure vaccine coverage, interpret results for action, and boost demand for vaccination using novel strategies.

Major studies evaluate the feasibility of using blood samples to identify gaps in immunity and implement mobile-based reminder systems, two approaches that could be adopted by governments to strengthen vaccination programs and protect all children.

Disease Epidemiology

To inform and improve prevention and control strategies, we manage large clinical studies and surveillance networks. We also quantify the amount of disease in countries and globally via mathematical models constructed with an understanding of population-level epidemiology, health system, and policy contexts.

Economics & Finance

To support investment and funding decisions, we quantify the cost of illness from diseases and determine the economic return on investment of vaccine use. We also help countries identify and address financing and affordability challenges.

Impact Evaluation

To inform policy & investments, we evaluate how vaccines reduce the spread of disease and create other value post introduction and over time.

Operations Research

To support the introduction of new vaccines and improvements in coverage, we analyze the programmatic and logistical implications of policy choices, such as variations in shipping, packaging, and other operational decisions that affect cost and health impact. Digital tools aid countries in designing, planning, and improving supply chains.

Policy Engagement

As a leading contributor to global immunization policy, we synthesize & present evidence to build consensus, inform strategy and support policy development. Members of IVAC’s leadership serve on the WHO Strategic Advisory Group of Experts (SAGE) and on several WHO working groups.

Technical Advocacy

To advance evidence-based policy, we support technically driven efforts, led by global and in-country partners, to understand the value of vaccines. We develop compendiums of published evidence, formulate messaging, and develop advocacy materials. We also build and manage coalitions and networks of scientists and other health advocates.

Baltimore City Partnership

Evaluation of Baltimore City Health Department Influenza Immunization Initiative Challenge There is concern about an increase in rates of both influenza and COVID-19 illnesses and deaths this coming 2020-2021 flu season and Baltimore City has committed to reaching the ambitious target of vaccinating at least 70% of its residents against influenza. Last season, although reporting […]

Read More >

Coalition to Strengthen the HPV Immunization Community (CHIC)

Coalition to Strengthen the HPV Immunization Community (CHIC) The challenge Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide and affects both sexually active men and women. HPV is preventable through effective screening and vaccination measures. To combat cervical cancer, it is essential to advocate for building and supporting optimized local programs, guiding […]

Read More >

Community Health Worker-Led Intervention for Vaccine Information and Confidence

Community Health Worker-Led Intervention for Vaccine Information and Confidence Challenge Although vaccinations are one of the most efficacious life-saving interventions, vaccine hesitancy is contributing to the resurgence of vaccine-preventable diseases (VPDs). Overcoming vaccine hesitancy and ensuring access to vaccinations has become even more critical considering the COVID-19 pandemic, as this has disrupted normal vaccine-seeking behavior. […]

Read More >

Effect of Age on Pneumococcal Vaccine Immunogenicity in Adults Over 50 Years of Age

Effect of Age on Pneumococcal Vaccine Immunogenicity in Adults Over 50 Years of Age CHALLENGE Many high income countries recommend immunization with pneumococcal polysaccharide vaccine and/or pneumococcal conjugate vaccines for adults over 50 years of age. WHO guidance to countries globally regarding adult immunization in the context of widespread use of infant PCV programs is […]

Read More >

Missed Opportunities for Vaccine Equity (MOVE)

The study will elucidate the novel problem of missed opportunities during hospitalization by quantifying the proportion of under-vaccinated children who remain unvaccinated at the time of hospital discharge. Our study is designed to systematically collect the vaccination status of hospitalized children at the time of admission and discharge, while also documenting caregivers’ and healthcare providers’ perspectives on barriers to vaccine access.

Read More >